Newbioideas

Natural product therapy targeting aberrant Lipid synthesis in Human cancers: 8-hydrocalamenene, derived from Reynoutria elliptica, suppresses the expression of the principal enzyme in lipid synthesis, ACLY, inhibits aberrant lipid production in cancer cells and tumor progression via up regulation of its target gene


AMOUNT: $ 300

A recent study from Rutgers Cancer Institute of New Jersey, Rutgers University, The State University of New Jersey, New Brunswick, New Jersey, USA shows that “Cullin3–KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression.” This study was published in the 1 September 2016 issue of Genes Development by Prof Feng Z, Zhang C, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product therapy targeting aberrant Lipid synthesis in Human cancers: 8–hydrocalamenene, derived from Reynoutria elliptica, suppresses the expression of the principal enzyme in lipid synthesis, ACLY, inhibits aberrant lipid production, and tumor progression via up regulation of its target gene

Significance:

Given that cancer causes the highest economic loss compared to all the known causes of human death worldwide, there is an urgent need to find: (i) a cheaper alternative to the existing expensive drugs; (ii) a side-effect-free natural product-based drug that targets abnormal bio-fuel requirements of cancer cells; (iii) a way to effectively treat cancers that are resistant to anti-cancer drugs; and (iv) a way to effectively treat and eradicate metastatic progression of cancer.

Figure1: 8-Hydrocalamenene, isolated from Reynoutria elliptica, inhibits abnormal lipid synthesis and cancer progression via down-regulation of ACLY

This study suggests, for the first time, that 8–hydrocalamenene, by increasing the expression of its target gene, it may suppress the expression of ATP-Citrate lyase (ACLY). Remarkably, a number of human tumors over-express ACLY, suggesting that inhibition of its activity may inhibit aberrant lipid synthesis in cancer cells, and thereby increase the efficacy of anticancer therapy.

Thus, pharmacological formulations encompassing “8–hydrocalamenene or its analogue” may be used to treat human cancers that specifically overexpress ACLY.

Idea Proposed/Formulated by: Dr L Boominathan Ph.D.

Web: http://genomediscovery.org or http://newbioideas.com

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To cite: Boominathan, Natural product therapy targeting aberrant Lipid synthesis in Human cancers: 8–hydrocalamenene, derived from Reynoutria elliptica, suppresses the expression of the principal enzyme in lipid synthesis, ACLY, inhibits aberrant lipid production in cancer cells and tumor progression via up regulation of its target gene, 8/October/2016, 11.07 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

# Research cooperation

Amount: $300#

satisfaction-guarantee

Results guaranteed if not refunded

Undisclosed information: How 8–hydrocalamenene inhibits the expression of ACLY

REGISTER

   

Dr.Boominathan PhD

Dr Boominathan was the first one in the world to propose a p73/p63-dependent cancer suppressor pathway (Supported by a legally valid Invention disclosure document certified by an advocate-2002/3)

Add comment

Most popular